LOS ANGELES, July 5, 2018 /PRNewswire/ -- Stellar
Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a
key protein utilized in multiple immunotherapy development
pipelines, today issued a statement on the favorable Phase
2b study results published by
Neovacs, S.A., a customer and joint venture partner.
The following is a statement from Frank
R. Oakes, Stellar's Chairman of the Board, President and
Chief Executive Officer:
We would like to extend our
congratulations to Neovacs on the encouraging results achieved in
its Phase 2b study and on the
continuing advancement of their IFN-Alpha-Kinoid immunotherapy in
systemic lupus erythematosus, which the Lupus Foundation has
described as 'one of the world's cruelest, most unpredictable and
devastating diseases.' In addition to achieving key endpoints,
Neovacs reported potent and long-lasting biological activity of
their therapeutic vaccine, which utilizes Stellar KLH as a carrier
molecule. The KLH-conjugated vaccine also demonstrated a favorable
safety profile among study participants. The conclusion of this
study is an important milestone for Neovacs as well as for Stellar.
We believe these results will help to reinforce the role of Stellar
KLH as a key component in immunotherapy treatments.
We look forward to working with
Neovacs as it prepares for its pivotal Phase 3 clinical studies.
Stellar remains focused and fully committed to ensuring the
environmentally sound production of KLH to meet the increased
volumes required by Neovacs for Phase 3 trials, manufacturing
validation and scale-up.
About Stellar Biotechnologies
Based north of
Los Angeles at the Port of
Hueneme, Stellar Biotechnologies, Inc. is the leader in
sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an
immune-stimulating protein utilized as a carrier molecule in
therapeutic vaccine pipelines (targeting cancers, immune disorders,
Alzheimer's and inflammatory diseases) and for assessing immune
system function. KLH can also be used in immunotoxicology studies
for monitoring the immunomodulatory effects of drug candidates.
Stellar is committed to meeting the growing demand for
commercial-scale supplies of GMP grade KLH, ensuring
environmentally sound KLH production, and supporting the
development of KLH-based active immunotherapies. Stellar KLH is a
trademark of Stellar Biotechnologies.
Follow Stellar: LinkedIn | Twitter | Facebook | Google+
Stellar Forward-Looking Statements
This press
release may contain forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements may be identified by the use of words
such as "anticipate," "believe," "plan," "estimate," "expect,"
"intend," "may," "will," "would," "could," "should," "might,"
"potential," or "continue" and variations or similar expressions.
Readers should not unduly rely on these forward-looking statements,
which are not a guarantee of future performance. There can be no
assurance that forward-looking statements will prove to be
accurate, as all such forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause
actual results or future events to differ materially from the
forward-looking statements. Such risks include, but may not be
limited to: general economic and business conditions; technology
changes; competition; changes in strategy or development plans;
availability of funds and resources; anticipated requirements for
operating capital; governmental regulations and the ability or
failure to comply with governmental regulations; changes in trade
policy and international law; the timing of Stellar's or its
partners' anticipated results, including in connection with
clinical trials; the ability to meet the goals of Stellar's joint
ventures and strategic partnerships; and other factors referenced
in Stellar's filings with securities regulators. For a discussion
of further risks and uncertainties related to the Stellar's
business, please refer to Stellar's public company reports filed
with the U.S. Securities and Exchange Commission and the British
Columbia Securities Commission. All forward-looking statements are
made as of the date hereof and are subject to change. Except as
required by law, Stellar assumes no obligation to update such
statements. This press release does not constitute an offer or
solicitation of an offer for sale of any securities in any
jurisdiction, including the United
States.
View original
content:http://www.prnewswire.com/news-releases/stellar-issues-statement-on-favorable-clinical-study-results-300676397.html
SOURCE Stellar Biotechnologies, Inc.
